Medexus Pharmaceuticals, Inc. is a leading innovative specialty pharmaceutical company with a strong North American commercial platform. Our product portfolio features leading products that address a variety of diseases, including allergy, dermatology, hematology, oncology and rheumatology.
The leading prescription products are Rasuvo and Metoject, unique formulations of methotrexate (auto-injector and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, an innovative allergy medication with a unique mode of action; IXINITY, for control & prevention of bleeding episodes & for perioperative management of patients with Hemophilia B; Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery; and Trecondyv, indicated in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT).